<?xml version="1.0" encoding="UTF-8"?>
<table-wrap id="Tab2">
 <label>Table 2</label>
 <caption>
  <p>Principal therapeutic interventions currently under investigation</p>
 </caption>
 <table frame="hsides" rules="groups">
  <thead>
   <tr>
    <th>Treatment goal</th>
    <th>Drug</th>
    <th>Target</th>
   </tr>
  </thead>
  <tbody>
   <tr>
    <td rowspan="4">
     <bold>Anti-viral growth</bold>
    </td>
    <td>
     <italic>Ritonavir, prezcobix</italic>
    </td>
    <td>
     <italic>•</italic> HIV protease Inhibitor
    </td>
   </tr>
   <tr>
    <td>
     <italic>Remdesivir, favipiravir</italic>
    </td>
    <td>
     <italic>•</italic> RNA polymerase inhibitors
    </td>
   </tr>
   <tr>
    <td>
     <italic>Hydroxychloroquine</italic>
    </td>
    <td>
     <italic>•</italic> Not clearly known. Modify pH of endosomes and prevents viral entry, transport and post-entry events
    </td>
   </tr>
   <tr>
    <td>
     <italic>Ivermectine</italic>
    </td>
    <td>
     <italic>•</italic> Different anti-viral activity
    </td>
   </tr>
   <tr>
    <td colspan="3">
     <bold>Anti-inflammatory</bold>
    </td>
   </tr>
   <tr>
    <td> Interferon</td>
    <td>
     <italic>IFNα inh, IFNβ1a</italic>
    </td>
    <td>
     <italic>•</italic> IFNα inh, IFNβ1a
    </td>
   </tr>
   <tr>
    <td> Monoclonal antibodies</td>
    <td>
     <p>Tocilizumab/sarilumab/siltuximab</p>
     <p>
      <italic>Anakinra</italic>
     </p>
     <p>
      <italic>Gimsilumab</italic>
     </p>
     <p>
      <italic>Thalidomide</italic>
     </p>
    </td>
    <td>
     <p>
      <italic>•</italic> Anti-IL-6
     </p>
     <p>
      <italic>•</italic> Anti-IL-1
     </p>
     <p>
      <italic>•</italic> Anti-GM-GSF
     </p>
     <p>
      <italic>•</italic> Anti-TNFα
     </p>
    </td>
   </tr>
   <tr>
    <td> Anti gout</td>
    <td>
     <italic>Colchicine</italic>
    </td>
    <td>
     <italic>•</italic> Tubulin disruption
    </td>
   </tr>
   <tr>
    <td> Antibiotics</td>
    <td>
     <italic>Azithromycin, clarithromycin</italic>
    </td>
    <td>
     <italic>•</italic> Protease inhibitors (?)
    </td>
   </tr>
   <tr>
    <td>
     <bold>Reduce organ failure</bold>
    </td>
    <td>
     <italic>Losartan</italic>
    </td>
    <td>
     <italic>•</italic> RAAS inhibitor
    </td>
   </tr>
   <tr>
    <td>
     <bold>Immune modulation regeneration</bold>
    </td>
    <td>
     <italic>Mesenchymal stem cells</italic>
    </td>
    <td/>
   </tr>
   <tr>
    <td rowspan="3">
     <bold>Pulmonary complications</bold>
    </td>
    <td>
     <italic>AiRuiKa</italic>
    </td>
    <td>
     <italic>•</italic> PD-1 inhibitor
    </td>
   </tr>
   <tr>
    <td>
     <italic>Avastin</italic>
    </td>
    <td>
     <italic>•</italic> VEGF inhibitor
    </td>
   </tr>
   <tr>
    <td>
     <italic>iNO/Sildenafil</italic>
    </td>
    <td>
     <italic>•</italic> Pulmonary smooth muscle
    </td>
   </tr>
   <tr>
    <td>
     <bold>Passive immunity</bold>
    </td>
    <td>
     <italic>Convalescent plasma</italic>
    </td>
    <td>
     <italic>•</italic> Passive immunization
    </td>
   </tr>
   <tr>
    <td>
     <bold>Active immunity</bold>
    </td>
    <td>
     <italic>Vaccines</italic>
    </td>
    <td>
     <italic>•</italic> Anti-SARS-CoV-2
    </td>
   </tr>
  </tbody>
 </table>
 <table-wrap-foot>
  <p>
   <italic>RAAS</italic> renin–angiotensin–aldosterone system, 
   <italic>iNO</italic> inhaled Nitric Oxide
  </p>
 </table-wrap-foot>
</table-wrap>
